NICE accepts PAD treatment

Intermittent claudication can significantly impair mobility in people with PAD. | SCIENCE PHOTO LIBRARY
Intermittent claudication can significantly impair mobility in people with PAD. | SCIENCE PHOTO LIBRARY

Naftidrofuryl oxalate can now be prescribed on the NHS for the treatment of intermittent claudication caused by peripheral arterial disease (PAD). It may be used in patients for whom vasodilator therapy is considered appropriate.

Although naftidrofuryl oxalate does not halt the progression of PAD, it is believed to be the most clinically and cost effective treatment option in terms of improving maximum walking distance.

NICE rejected the other vasodilators cilostazol, pentoxifylline and inositol nicotinate for intermittent claudication in PAD on the grounds that they are not as clinically effective compared with placebo as naftidrofuryl oxalate.

View naftidrofuryl drug record


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases